A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans: A randomized and prospective study with an angiotensin II receptor blocker

International Heart Journal

Volumn 48, Issue 6, 2007, Pages 715-724

  Yamazaki, Tadashi ^a   Suzuki, Jun Ichi ^a   Shimamoto, Ryoichi ^a   Tsuji, Taeko ^a   Ohmoto Sekine, Yuki ^a   Ohtomo, Kuni ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II receptor blockers; Hypertrophic nonobstructive cardiomyopathy; Left ventricular mass; Magnetic resonance

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN POTASSIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE DISPLAY; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LOSARTAN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 37649017852     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.715     Document Type: Article

References (22)

1. Osterop AP, Kofllard MJ, Sandkuijl LA, et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998; 32: 825-30.
2. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Ciculation 2003; 107: 2227-32.
3. Anan R, Niinium H, Takenaka T, Hamasaki S, Tei C. Mutations in the genes for sarcomeric: proteins in Japanese patients with onset sporadic hypertrophic cardiormyopathy after age 40 years. Am J Cardiol 2007-199: 1750-4.
4. Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol 2001; 38: 1175-80.
5. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38: 315-21.
6. Deinum J, von Gool JM, Kofflard MJ, ten Cate FJ, Danser AH. Angiotensin H type 2 receptor and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001; 38: 1278-81.
7. Suzuki J, Shimamoto R, Nishikawa J, et al. Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: a long-term analysis with nuclear magnetic resonance imaging. J Am Coll Cardiol 1999; 33: 146-51.
8. Suzuki J, Chang JM, Caputo GR, Higgins CB. Evaluation of right ventricular early diastolic filling by cine nuclear magnetic resonance imaging in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 1991; 18: 120-6.
9. Richardson P, Mckenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-2.
10. Yamazaki T, Suzuki J, Shimamoto R, et al. Focalized contractile impairment at hypertrophied myocardial proven in consideration of wall stress in patients with hypertrophic cardiomyopathy. Int Heart J 2006; 47: 247-58.
11. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium; function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-92. (Review)
12. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognosis importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45: 1076-80.
13. Araujo AQ, Aeteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005; 96: 1563-7.
14. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic: mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103: 789-91.
15. Masutomo K, Makino N, Fushiki MS. Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters. Mol Cell Biochem 2001; 224: 19-27.
16. Ujiie Y, Hirosaka A, Mitsugi M, et al. Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis. Int Heart J 2006; 47: 173-84.
17. Yamazaki T, Komuro I, Kudoh S, et al. Angiotensin II party mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995; 77: 258-65.
18. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventriculm hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
19. Iwase M, Kondo T, Hasegawa K, et al. Three-dimensional echocardiography by semi-automatic border detection in assessment of left ventricular volume and ejection fraction: comparison with magnetic resonance imaging. J Cardiol 1997; 30: 97-105.
20. Solar M, Zizka J, Dolezal J, et al. Contrast-enhanced magnetic resonance and thallium scintigraphy in the detection of myocardial viability. Int Heart J 2006; 47: 521-32.
21. Bunch TJ, Chandrasekaran Y, Ehrsam JE, et al. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy. Am J Cardiol 2007; 99: 835-8.
22. Usui M, Inoue H, Suzuki J, Watanabe F, Sugimoto T, Nishikawa J. Relationship between distribution of hypertrophy and electrocardiographic changes in hypertrophic cardiomyopathy. Am Heart J 1993; 126: 177-83.